Fluciclovine (18F) Imaging of Breast Cancer

Exclusion Criteria

• •1. Pregnant or breastfeeding women
• •2. Major surgery or significant traumatic injury within four weeks prior to enrolment.
• •3. Treatment with any other investigational agent, or participation in another interventional clinical study within 4 weeks prior to enrolment.
• •4. Multifocal breast cancer (defined as more than two tumours, either unilateral or bilateral).
• •5. Known hypersensitivity to fluciclovine (18F) or any of its constituents.
• •6. Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor study candidate or could interfere with protocol compliance or the interpretation of study results.
• •7. Any other active malignancy or any previous diagnosis of melanoma.